Literature DB >> 28666734

A novel inhibitor of farnesyltransferase with a zinc site recognition moiety and a farnesyl group.

Ayumi Tanaka1, Mohamed O Radwan2, Akiyuki Hamasaki1, Asumi Ejima1, Emiko Obata1, Ryoko Koga1, Hiroshi Tateishi1, Yoshinari Okamoto1, Mikako Fujita3, Mitsuyoshi Nakao4, Kazuo Umezawa5, Fuyuhiko Tamanoi6, Masami Otsuka7.   

Abstract

Protein prenylation such as farnesylation and geranylgeranylation is associated with various diseases. Thus, many inhibitors of prenyltransferase have been developed. We report novel inhibitors of farnesyltransferase with a zinc-site recognition moiety and a farnesyl/dodecyl group. Molecular docking analysis showed that both parts of the inhibitor fit well into the catalytic domain of farnesyltransferase. The synthesized inhibitors showed activity against farnesyltransferase in vitro and inhibited proliferation of the pancreatic cell line AsPC-1. Among the compounds with farnesyl and dodecyl groups, the inhibitor with a farnesyl group was found to have stronger and more selective activity.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Farnesyl group; Farnesyltransferase; Ras protein; Zinc protein

Mesh:

Substances:

Year:  2017        PMID: 28666734     DOI: 10.1016/j.bmcl.2017.06.047

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  9 in total

Review 1.  KRAS G12C Game of Thrones, which direct KRAS inhibitor will claim the iron throne?

Authors:  Misako Nagasaka; Yiwei Li; Ammar Sukari; Sai-Hong Ignatius Ou; Mohammed Najeeb Al-Hallak; Asfar S Azmi
Journal:  Cancer Treat Rev       Date:  2020-01-23       Impact factor: 12.111

Review 2.  Targeting prenylation inhibition through the mevalonate pathway.

Authors:  Pimyupa Manaswiyoungkul; Elvin D de Araujo; Patrick T Gunning
Journal:  RSC Med Chem       Date:  2019-12-23

3.  Design, Synthesis, and Biological Evaluation of Novel 1,3,4-Thiadiazole Derivatives as Potential Antitumor Agents against Chronic Myelogenous Leukemia: Striking Effect of Nitrothiazole Moiety.

Authors:  Mehlika Dilek Altıntop; Halil Ibrahim Ciftci; Mohamed O Radwan; Belgin Sever; Zafer Asım Kaplancıklı; Taha F S Ali; Ryoko Koga; Mikako Fujita; Masami Otsuka; Ahmet Özdemir
Journal:  Molecules       Date:  2017-12-27       Impact factor: 4.411

4.  Antiproliferative S-Trityl-l-Cysteine -Derived Compounds as SIRT2 Inhibitors: Repurposing and Solubility Enhancement.

Authors:  Mohamed O Radwan; Halil I Ciftci; Taha F S Ali; Doha E Ellakwa; Ryoko Koga; Hiroshi Tateishi; Akiko Nakata; Akihiro Ito; Minoru Yoshida; Yoshinari Okamoto; Mikako Fujita; Masami Otsuka
Journal:  Molecules       Date:  2019-09-10       Impact factor: 4.411

5.  Design, Synthesis and Biological Evaluation of Pentacyclic Triterpene Derivatives: Optimization of Anti-ABL Kinase Activity.

Authors:  Halil I Ciftci; Mohamed O Radwan; Safiye E Ozturk; N Gokce Ulusoy; Ece Sozer; Doha E Ellakwa; Zeynep Ocak; Mustafa Can; Taha F S Ali; Howaida I Abd-Alla; Nurettin Yayli; Hiroshi Tateishi; Masami Otsuka; Mikako Fujita
Journal:  Molecules       Date:  2019-09-30       Impact factor: 4.411

6.  Novel Inhibitor for Downstream Targeting of Transforming Growth Factor-β Signaling to Suppress Epithelial to Mesenchymal Transition and Cell Migration.

Authors:  Tsugumasa Toma; Hiroshi Tateishi; Kensaku Kawakami; Taha F S Ali; Masahiro Kamo; Kazuaki Monde; Yuta Nakashima; Mikako Fujita; Masami Otsuka
Journal:  Int J Mol Sci       Date:  2022-05-02       Impact factor: 5.923

7.  Deciphering Pathways for Carotenogenesis in Haloarchaea.

Authors:  Micaela Giani; Jose María Miralles-Robledillo; Gloria Peiró; Carmen Pire; Rosa María Martínez-Espinosa
Journal:  Molecules       Date:  2020-03-06       Impact factor: 4.411

Review 8.  Current therapy of KRAS-mutant lung cancer.

Authors:  Aron Ghimessy; Peter Radeczky; Viktoria Laszlo; Balazs Hegedus; Ferenc Renyi-Vamos; Janos Fillinger; Walter Klepetko; Christian Lang; Balazs Dome; Zsolt Megyesfalvi
Journal:  Cancer Metastasis Rev       Date:  2020-12       Impact factor: 9.264

Review 9.  Targeting KRAS in NSCLC: Old Failures and New Options for "Non-G12c" Patients.

Authors:  Francesca Jacobs; Massimiliano Cani; Umberto Malapelle; Silvia Novello; Valerio Maria Napoli; Paolo Bironzo
Journal:  Cancers (Basel)       Date:  2021-12-16       Impact factor: 6.639

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.